ProstaScint

ProstaScint is a radiopharmaceutical agent used in the imaging and staging of prostate cancer. It is a type of monoclonal antibody that is linked to a radioactive substance, Indium-111. ProstaScint is designed to bind specifically to a protein called Prostate Specific Membrane Antigen (PSMA), which is found on the surface of prostate cancer cells.

Mechanism of Action

ProstaScint works by binding to PSMA on the surface of prostate cancer cells. The radioactive substance, Indium-111, emits gamma rays that can be detected by a gamma camera. This allows doctors to create an image of the cancer and determine its location and extent.

Uses

ProstaScint is used in the imaging and staging of prostate cancer. It can help doctors determine the extent of the cancer and whether it has spread to other parts of the body. This information is important for planning treatment and predicting prognosis.

Side Effects

Like all medications, ProstaScint can cause side effects. These may include allergic reactions, fever, and changes in blood counts. Patients should discuss potential side effects with their doctor before starting treatment.

History

ProstaScint was approved by the Food and Drug Administration (FDA) in 1996. It was the first radiopharmaceutical agent approved for the imaging of prostate cancer.

See Also

• Prostate cancer
• Radiopharmaceutical
• Monoclonal antibody
• Indium-111
• Prostate Specific Membrane Antigen
• Food and Drug Administration

ProstaScint Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski